{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1478","value":"1199.5"},{"groupId":"OG001","lowerLimit":"1746","upperLimit":"2671","value":"1759.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1, End Of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"712","upperLimit":"1305","value":"1078.0"},{"groupId":"OG001","lowerLimit":"1427","upperLimit":"1974","value":"1540.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 24 hours"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1137","upperLimit":"1659","value":"1576.0"},{"groupId":"OG001","lowerLimit":"1785","upperLimit":"1889","value":"1888.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 2-4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"428","upperLimit":"770","value":"576.5"},{"groupId":"OG001","lowerLimit":"751","upperLimit":"1087","value":"889.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"545","value":"358.0"},{"groupId":"OG001","lowerLimit":"487","upperLimit":"874","value":"737.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"326.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"551","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 4 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"346.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 6 Day 1, Pre-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of OX40 when administered intravenously in combination with belantamab mafodotin.","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8mg OX40"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8mg OX40"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population included all participants in the safety population from whom at least one PK sample has been obtained and analysed.","reportingStatus":"POSTED","timeFrame":"Up to Day 1 (End of Infusion) of Cycle 6 (Each Cycle consist of 21 days)","title":"DE Phase: OX40 Concentration When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}